Colfax Corporation operates as a diversified technology company worldwide.
+ 1 more risk
Reasonable growth potential and fair value.
Share Price & News
How has Colfax's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: C52's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: C52 exceeded the German Machinery industry which returned -8.7% over the past year.
Return vs Market: C52 exceeded the German Market which returned 4.4% over the past year.
Price Volatility Vs. Market
How volatile is Colfax's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Colfax undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: C52 (€26) is trading below our estimate of fair value (€42.7)
Significantly Below Fair Value: C52 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: C52 is poor value based on its PE Ratio (98.2x) compared to the Machinery industry average (17.6x).
PE vs Market: C52 is poor value based on its PE Ratio (98.2x) compared to the German market (20.1x).
Price to Earnings Growth Ratio
PEG Ratio: C52 is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: C52 is good value based on its PB Ratio (1.1x) compared to the DE Machinery industry average (1.4x).
How is Colfax forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: C52's forecast earnings growth (82.3% per year) is above the savings rate (0.2%).
Earnings vs Market: C52's earnings (82.3% per year) are forecast to grow faster than the German market (22.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: C52's revenue (8% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: C52's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: C52's Return on Equity is forecast to be low in 3 years time (7.5%).
How has Colfax performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: C52 has a large one-off loss of $130.1M impacting its April 3 2020 financial results.
Growing Profit Margin: C52's current net profit margins (1.2%) are lower than last year (2.7%).
Past Earnings Growth Analysis
Earnings Trend: C52's earnings have declined by -47% per year over the past 5 years.
Accelerating Growth: C52's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: C52 had negative earnings growth (-33.5%) over the past year, making it difficult to compare to the Machinery industry average (-20.2%).
Return on Equity
High ROE: C52's Return on Equity (1.5%) is considered low.
How is Colfax's financial position?
Financial Position Analysis
Short Term Liabilities: C52's short term assets ($1.6B) exceed its short term liabilities ($819.1M).
Long Term Liabilities: C52's short term assets ($1.6B) do not cover its long term liabilities ($3.3B).
Debt to Equity History and Analysis
Debt Level: C52's debt to equity ratio (76.1%) is considered high.
Reducing Debt: C52's debt to equity ratio has increased from 43.9% to 76.1% over the past 5 years.
Debt Coverage: C52's debt is not well covered by operating cash flow (10.2%).
Interest Coverage: C52's interest payments on its debt are not well covered by EBIT (2.8x coverage).
What is Colfax's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate C52's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate C52's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if C52's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if C52's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of C52's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Trerotola (52yo)
Mr. Matthew L. Trerotola, also known as Matt, has been the Chief Executive Officer of Colfax Corporation since July 24, 2015 and has been its President since July 2015. Mr. Trerotola has been the President ...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD8.43M) is above average for companies of similar size in the German market ($USD2.40M).
Compensation vs Earnings: Matt's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|Co-Founder & Chairman of the Board||no data||US$1.00||7.37% $231.3m|
|Executive VP of Finance & CFO||3.92yrs||US$4.15m||0.012% $383.9k|
|Executive Vice President of Strategy & Business Development||6.92yrs||US$2.98m||0.071% $2.2m|
|Executive VP and CEO & President of ESAB||4.08yrs||US$3.06m||0.048% $1.5m|
|Chief Executive Officer of DJO||3.58yrs||US$4.44m||no data|
|Interim Senior Vice President of Global Operations & Americas||no data||no data||no data|
|Vice President of Investor Relations||5.5yrs||no data||no data|
|Senior VP||1.33yrs||no data||no data|
|Senior VP & Chief Human Resources Officer||1.42yrs||no data||no data|
Experienced Management: C52's management team is considered experienced (4.1 years average tenure).
|Co-Founder & Chairman of the Board||no data||US$1.00||7.37% $231.3m|
|Independent Director||12.08yrs||US$228.19k||0.18% $5.8m|
|Independent Director||9.75yrs||US$233.19k||0.0063% $197.4k|
|Independent Director||12.08yrs||US$213.19k||0.049% $1.5m|
|Independent Director||12.08yrs||US$213.19k||0.020% $628.4k|
|Independent Director||2.75yrs||US$213.19k||0.016% $517.3k|
|Independent Director||11.33yrs||US$228.19k||0.021% $663.3k|
|Independent Director||0.42yr||no data||0.0081% $255.2k|
Experienced Board: C52's board of directors are seasoned and experienced ( 10.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: C52 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Colfax Corporation's company bio, employee growth, exchange listings and data sources
- Name: Colfax Corporation
- Ticker: C52
- Exchange: DB
- Founded: 1860
- Industry: Industrial Machinery
- Sector: Capital Goods
- Market Cap: US$3.556b
- Listing Market Cap: US$3.139b
- Shares outstanding: 118.33m
- Website: https://www.colfaxcorp.com
Number of Employees
- Colfax Corporation
- 420 National Business Parkway
- 5th Floor
- Annapolis Junction
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CFX||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 2008|
|C52||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2008|
|0I1B||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2008|
Colfax Corporation operates as a diversified technology company worldwide. The company operates through two segments, Medical Technology and Fabrication Technology. The Medical Technology segment offers orthopedic solutions, including orthopedic devices and braces, reconstructive and surgical implants, footwear, bone growth stimulators, and software and services spanning the full continuum of patient care, as well as injury prevention, rehabilitation, pain management, and physical therapy under the Aircast, Chattanooga, CMF, Compex, DonJoy, ProCare, DJO Surgical, Dr. Comfort, Exos, and MotionMD brand names. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent salespersons. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding of steels, aluminum, and other metals and metal alloys. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips under the ESAB brand name. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine, pipelines, mobile/off-highway equipment, oil, gas, and mining markets. Colfax Corporation was founded in 1860 and is headquartered in Annapolis Junction, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 22:25|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.